Hodgkin’s lymphoma in pediatric patients involves chemotherapy drug regimens containing Dacarbazine as a backbone of the therapy. Adverse drug events are the major concerns in the treatment plan of chemotherapy. Here in this case series, we present five cases of Hodgkin’s lymphoma of pediatric age group getting treated with Dacarbazine based chemotherapy either COPDac or ABVD. All patients developed shivering during the infusion. Three of them had fever spikes and one patient happened to have tachycardia. All the events were managed conservatively followed by safe administration of chemotherapy. Four patients are continuing to have treatment as per the plan and one patient is with end of treatment and on follow up. Naranjo’s scale was used for probability assessment of the events and score of 6 was given to all the events, indicating the adverse drug reactions to be probable. A very scarce data and our case series are evocative of further studies to review the administration time of the Dacarbazine as well as the addition of pre-medication before initiation of Dacarbazine infusion.

 

Keywords: Pediatric Hodgkin’s Lymphoma, Adverse Drug Reactions, Dacarbazine, Case Series 

 

Abbreviations: PHL-Pediatric Hodgkin’s Lymphoma; COPDac-Cyclophosphamide, Vincristine, Prednisone, Dacarbazine; ABVD-Adriamycin, Bleomycin, Vinblastine, Dacarbazine; OEPA -Vincristine, Etoposide, Prednisone, Adriamycin), ADR-Adverse Drug Reaction